About alvotech - ALVO
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
ALVO At a Glance
Alvotech
9, rue de Bitbourg
Luxembourg, Luxembourg 1273
| Phone | 352-422-4500 | Revenue | 91.43M | |
| Industry | Biotechnology | Net Income | -551,731,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 10.123% | |
| Fiscal Year-end | 12 / 2024 | Employees | 1,026 | |
| View SEC Filings |
ALVO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 28.533 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -11.103 |
| Enterprise Value to Sales | 40.173 |
| Total Debt to Enterprise Value | 0.293 |
ALVO Efficiency
| Revenue/Employee | 89,116.959 |
| Income Per Employee | -537,749.513 |
| Receivables Turnover | 1.048 |
| Total Asset Turnover | 0.103 |
ALVO Liquidity
| Current Ratio | 0.747 |
| Quick Ratio | 0.461 |
| Cash Ratio | 0.043 |
ALVO Profitability
| Gross Margin | -85.362 |
| Operating Margin | -388.29 |
| Pretax Margin | -704.219 |
| Net Margin | -603.42 |
| Return on Assets | -62.043 |
| Return on Equity | N/A |
| Return on Total Capital | -385.877 |
| Return on Invested Capital | -354.948 |
ALVO Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 752.18 |
| Total Debt to Total Assets | 113.197 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 718.813 |